Cabrini Monash University Department of Medical Oncology – The Szalmuk Family Department of Medical Oncology Head: Professor Gary Richardson OAM The department undertakes a wide range of research activities, largely building upon the second largest clinical service in Victoria (the largest private service in Australia). Activities include new drug trials, translational research in breast, colorectal and ovarian cancers, medical informatics and patient-reported outcome measures.
Head of Department Professor Gary Richardson OAM (Phase I trials, Gynaecologic Cancers, Lung Cancer) Principal Investigators Dr Yoland Antill (Breast Cancer) Associate Professor Ben Brady (Melanoma, Lung Cancer) Dr Anis Hamid (Phase I trials) Dr Andrew Haydon (Gastrointestinal Cancers, Melanoma) Associate Professor Melita Kenealy (Haematologic Malignancies) Associate Professor Lara Lipton (Gastrointestinal Cancers) Dr David Pook (Genitourinary Cancers)
Associate Professor Jeremy Shapiro (Gastrointestinal Cancers, Genitourinary Cancers) Associate Investigators Dr Michael Dickinson Dr Lucy Gately Associate Professor Ian Haines Dr Despina Handolias Dr Henry Januszewicz Dr Sem Liew Dr Esther Lin Dr Ben Markman Professor Miles Prince Dr Gaurav Srivastava Dr Robert Stanley Dr Mark Voskoboynik Dr Michelle White Associate Professor Max Wolff Dr Kirsten Herbert Dr Dan Tran Dr Emma Beardsley
Dr Samantha Dean Dr Peter Lau Dr Jo Ann Chow Senior Research Fellow Dr Tali Lang Research Coordinators Li Hoon Lai (Team Leader) Demis Balamatsias Lyanne Cottee Theresa Ealdama Kate Hurford Simona Infantino Simer Khaira Leyna Tran Rochelle Woods CTA Ethics Specialist Dr Luz YĂŠvenes
Brightways Breast Cancer Program Dr Joanna Morgan, Specialist Breast, Thyroid and Parathyroid Surgeon Dr Karen Taylor, Radiation Oncologoist Melissa Vereker, Data Manager and MDT Meeting Coordinator Acknowledgement of Research Coordinator Staff who have left (2019-2020) Daphne Antonopoulos, Research Coordinator Stephanie Groube, Associate Genetic Counsellor Jacqui Hastings, Acting Brightways Coordinator Anna Uhe, Clinical Trials Assistant
Family Cancer Clinic Lynne McKaye, Genetic Counsellor
The program provides significant benefits for patients, including access to treatments not yet in the marketplace, close monitoring and testing, and collection of valuable information that can help others. The department is seen as a partner of choice by the pharmaceutical and biotech industries, particularly in the area of precision medicine. We have a highly trained dedicated team that provide the highest level of care for all patients participating in clinical trials. Development and maintenance of a robust research program not only benefits patients in terms of access to new active anti-cancer agents. It also allows us to attract the best and brightest researchers and clinicians, who improve the consumer experience even more.
C A B R I N I I N S T I T U T E A N N U A L R E P O RT 2 0 1 9 -2 0
51
